@inbook{03352fc52baf43a9a48c0a467b48bb09,
title = "First-line treatment and survival of transformed follicular lymphoma in the netherlands in the rituximab era; a population-based analysis",
abstract = "Introduction: Treatment of transformed follicular lymphoma (TFL) is diverse as there are no randomized studies to guide therapy. Patients are treated with rituximab (R)-chemotherapy only or with R-chemo and upfront autologous stem cell transplantation (ASCT) at their physicians' discretion. We investigated different treatment modalities and outcome of patients registered in the Population-based Haematological Registry for Observational Studies (PHAROS), covering 40% of the Dutch population. Methods: From the PHAROS registry, we extracted all patients with a diagnosis of both follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) between January 2004 and July 2013 and checked their histology. Only patients with biopsy-proven DLBCL and underlying FL (previously or simultaneously diagnosed) were included. A separate analysis was performed on patients below 68 years, since upfront ASCT was given up to 67 years. Results: One hundred and sixty-one patients were included, median age at transformation was 63 years (34-91), median time to TFL was 14 months (0-101) and median follow-up after transformation was 17 months (1-111). Former treatment for FL: Sixty-one per cent had been treated with chemotherapy for FL (66% of them with R), 2% had received radiotherapy only, 24% were under a watch-and-wait strategy and, in 13%, FL and DLBCL were diagnosed simultaneously. Treatment for TFL: Ten patients were unable to receive any treatment. All 151 treated patients received R-chemo as induction therapy: 62 patients (33,",
keywords = "Netherlands, autologous stem cell transplantation, biopsy, chemotherapy, diagnosis, follicular lymphoma, follow up, histology, human, ibritumomab tiuxetan, large cell lymphoma, lymphoma, mortality, observational study, patient, physician, population, prognosis, radiotherapy, register, remission, rituximab, survival, therapy, yttrium 90",
author = "Wondergem, {M J} and Issa, {D E} and Zijlstra, {J M} and O Visser and S Zweegman and Chamuleau, {M E}",
year = "2015",
language = "English",
isbn = "0278-0232",
series = "Hematological Oncology",
pages = "265--266",
booktitle = "Hematological Oncology",
}